ABC | Volume 115, Nº1, July 2020

Original Article Macedo et al. Resistant hypertension in afrodescendants Arq Bras Cardiol. 2020; 115(1):31-39 Table 2 – Systolic blood pressure, diastolic blood pressure, diagnosis time and follow-up time for patients seen at a referral center, according to resistant or refractory hypertension Characteristics Hypertension RH RfH p- value Mean (SD) Mean (SD) SBP (mmHg) 145.8 (24.8) 158.7 (29.6) 0.008 DBP (mmHg) 84.3 (14.1) 92.0 (20.0) 0.012 Time since SAH diagnosis (years) 19.2 (11.9) 23.12 (13.0) 0.078 Follow-up time (years) 10.7 (6.1) 11.38 (10.3) 0.665 SBP: systolic blood pressure; DBP: diastolic blood pressure; RH: resistant hypertension; RfH: refractory hypertension; SAH: systemic arterial hypertension; SD: standard deviation. Figure 1 – Proportion of use of antihypertensive medication, according to resistant or refractory hypertension. ACEI: angiotensin-converting enzyme inhibitor; BRA: angiotensin receptor blocker; BCC: calcium channel blocker; B-Block: beta blocker; RH: resistant hypertension; HRf: refractory hypertension. Figure 2 – Proportion of concomitant use of antihypertensive drugs (Angiotensin Conversion Inhibitor triad or Angiotensin Receptor Blocker + Calcium Channel Blocker + Diuretic), according to resistant or refractory hypertension. HR: resistant hypertension; HRf: refractory hypertension; P = 0.015; for difference in distribution of the use of the triad of antihypertensive drugs (ACEI or BRA + BCC + Thiazide diuretic) between HR versus HRf. Thiazide 120 93 91 42 23 52 75 79 96 66 76 100 80 60 40 20 00 medication use (%) ACEI BRA RH RfH BCC B-Bloq 100 Concomitant use (%) 90 80 70 60 50 40 30 20 25.4 RH RfH No Yes 74.6 9.9 90.1 10 0 35